Xconomy New York — Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study Can fish oil help prevent, or reduce the risk of heart disease? Several studies have failed to show that it can. But Amarin this morning is releasing data from a massive study showing that its prescription-grade fish oil […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-24 01:20:272018-09-25 01:29:35Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-24 01:11:542018-09-25 01:13:27AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
Point-of-care regenerative medicine technology approved to treat secondand third-degree burns using Spray-On Skin™ Cells product U.S. market launch planned for 4th calendar quarter 2018. Target market for burns approximates USD $200 million Valencia, Calif., USA, and Melbourne, Australia, 21 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company, today announced that […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-20 04:11:372018-09-21 04:31:29AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.
The FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials Based on the positive FDA feedback, AmpliPhi intends to seek […]
FDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials AmpliPhi expects to initiate one of these clinical trials in early 2019 AmpliPhi continues to investigate if […]
21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-17 04:04:532018-09-21 04:08:47AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program
By Christine Hall | September 12, 2018 The Texas Medical Center and the Department for International Trade in the United Kingdom formed a landmark BioBridge agreement Wednesday to provide a gateway for the advancement of life sciences between the two entities in the areas of innovation and research. The BioBridge, which included more than 18 months of preparation […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-13 02:12:212018-09-14 04:28:38Texas Medical Center forms ‘BioBridge’ with United Kingdom
10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]
23 Aug 2018 San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-23 02:46:062018-09-04 02:47:38Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD
Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study
/in SeaDragonXconomy New York — Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study Can fish oil help prevent, or reduce the risk of heart disease? Several studies have failed to show that it can. But Amarin this morning is releasing data from a massive study showing that its prescription-grade fish oil […]
AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
/in AmpliPhi BiosciencesProfessor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]
AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.
/in Avita MedicalPoint-of-care regenerative medicine technology approved to treat secondand third-degree burns using Spray-On Skin™ Cells product U.S. market launch planned for 4th calendar quarter 2018. Target market for burns approximates USD $200 million Valencia, Calif., USA, and Melbourne, Australia, 21 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company, today announced that […]
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections
/in AmpliPhi BiosciencesThe FDA is in general agreement with the design of two proposed randomized clinical trials of AB-PA01, hospital-acquired and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa and for P. aeruginosa bacteremia, and no additional preclinical or clinical data are required to proceed with both trials Based on the positive FDA feedback, AmpliPhi intends to seek […]
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01
/in AmpliPhi BiosciencesFDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials AmpliPhi expects to initiate one of these clinical trials in early 2019 AmpliPhi continues to investigate if […]
AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program
/in AmpliPhi Biosciences, Uncategorised21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]
Texas Medical Center forms ‘BioBridge’ with United Kingdom
/in BioSciences Managers, UncategorisedBy Christine Hall | September 12, 2018 The Texas Medical Center and the Department for International Trade in the United Kingdom formed a landmark BioBridge agreement Wednesday to provide a gateway for the advancement of life sciences between the two entities in the areas of innovation and research. The BioBridge, which included more than 18 months of preparation […]
Biopharma Company Arecor raises £6m for revolutionary diabetes treatments
/in Arecor10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]
Directorate Change New Chairman Appointment
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]
Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD
/in Adherium23 Aug 2018 San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its […]